NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000054609

Registered date:07/06/2024

A Biomarker-Based Evaluation Study of the Immediate Response of Ozoralizumab, an Anti-TNFa Antibody

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedRheumatoid arthritis
Date of first enrollment2024/05/16
Target sample size150
Countries of recruitmentJapan
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeComparison of mean change in CDAI at 24 weeks in the Ozoralizumab and Certolizumab pegol groups
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum18years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1) Patients with severe infections 2) Patients with active TB 3) Patients with a history of hypersensitivity to OZR 4) Patients with a history of demyelinating disease 5) Patients with congestive heart failure 6) Patients for whom TNF inhibitors are contraindicated in the Guidance on the Use of TNF Inhibitors for Rheumatoid Arthritis (revised 2023) by the Japan College of Rheumatology. 7) Other patients deemed inappropriate for the study by the principal investigator.

Related Information

Contact

public contact
Name Masanobu Ueno
Address 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan Japan 807-8555
Telephone 093-603-1611
E-mail masanobu-ueno@clnc.uoeh-u.ac.jp
Affiliation University of Occupational and Environmental Health, Japan First Department of Internal Medicine
scientific contact
Name Yoshiya Tanaka
Address 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan Japan
Telephone 093-603-1611
E-mail tanaka@med.uoeh-u.ac.jp
Affiliation University of Occupational and Environmental Health, Japan First Department of Internal Medicine